Hyperammonemia

Last updated
Hyperammonemia
Other namesHyperammonaemia; High ammonia levels
Ammonia lone electron pair.svg
Ammonia
Specialty Endocrinology   OOjs UI icon edit-ltr-progressive.svg
CausesDue to accumulation of argininosuccinate, citrulline, and arginine in the liver when the urea cycle is deficient.

Hyperammonemia, or high ammonia levels, is a metabolic disturbance characterised by an excess of ammonia in the blood. Severe hyperammonemia is a dangerous condition that may lead to brain injury and death. It may be primary or secondary.

Contents

Ammonia is a substance that contains nitrogen. It is a product of the catabolism of protein. It is converted to the less toxic substance urea prior to excretion in urine by the kidneys. The metabolic pathways that synthesize urea involve reactions that start in the mitochondria and then move into the cytosol. The process is known as the urea cycle, which comprises several enzymes acting in sequence. It is greatly exacerbated by common zinc deficiency, which raises ammonia levels further. [1]

Levels

Normal blood ammonia levels in adults range from 20 to 50 μmol/L or less than 26 to 30 μmol/L. [2] [3] [4] There is at present no clear scientific consensus on the upper limits of ammonia levels for different age groups. [4] In any case, hyperammonemia is generally defined as ammonia levels greater than 50 μmol/L in adults and greater than 100 μmol/L in newborns. [2] [4] These values should be considered as decision limits and the normal reference ranges of individual laboratories should be used for clinical interpretation. [4]

Blood ammonia levels in different populations [2] [3] [4]
Patient groupAmmonia levels (μmol/L)Hyperammonemia (μmol/L)Ref
Premature neonates50–159>159 [5] [3]
Healthy term neonates45–75>75–100 [5] [3]
Children and adolescents24–48>48–50 [6] [3]
Adult females11–48>48 [7]
Adult males15–55>55 [7]

When ammonia levels rise greater than 200 μmol/L, serious symptoms, including seizures, encephalopathy, coma, and even death, can occur. [3] Hyperammonemia with blood ammonia levels greater than 400 to 500 μmol/L is associated with 5- to 10-fold higher risk of irreversible brain damage. [2]

Signs and symptoms

Complication

Hyperammonemia is one of the metabolic derangements that contribute to hepatic encephalopathy, which can cause swelling of astrocytes and stimulation of NMDA receptors in the brain. [8]

Cause

Diagnosis

Types

Primary vs. secondary

Acquired vs. congenital

Specific types

The following list includes such examples:

Treatment

Treatment centres on limiting intake of ammonia and increasing its excretion. Dietary protein, a metabolic source of ammonium, is restricted, and caloric intake is provided by glucose and fat. Intravenous arginine (argininosuccinase deficiency), sodium phenylbutyrate and sodium benzoate (ornithine transcarbamylase deficiency) are pharmacologic agents commonly used as adjunctive therapy to treat hyperammonemia in patients with urea cycle enzyme deficiencies. [13] Sodium phenylbutyrate and sodium benzoate can serve as alternatives to urea for the excretion of waste nitrogen. Phenylbutyrate, which is the product of phenylacetate, conjugates with glutamine to form phenylacetylglutamine, which is excreted by the kidneys. Similarly, sodium benzoate reduces ammonia content in the blood by conjugating with glycine to form hippuric acid, which is rapidly excreted by the kidneys. [14] A preparation containing sodium phenylacetate and sodium benzoate is available under the trade name Ammonul. Acidification of the intestinal lumen using lactulose can decrease ammonia levels by protonating ammonia and trapping it in the stool. This is a treatment for hepatic encephalopathy. [15]

Treatment of severe hyperammonemia (serum ammonia levels greater than 1000 μmol/L) should begin with hemodialysis if it is otherwise medically appropriate and tolerated. [12]

Continuous renal replacement therapy (CRRT) is a remarkably effective mode of therapy in neonatal hyperammonemia, particularly in severe cases of Urea cycle defects like Ornithine transcarbamoylase (OTC) deficiency. Multidisciplinary team (MDT) collaboration is required to optimize this advanced treatment. Simulation training might be the best training and teaching strategy to ensure MDT successful therapy. [16]

See also

Related Research Articles

The urea cycle (also known as the ornithine cycle) is a cycle of biochemical reactions that produces urea (NH2)2CO from ammonia (NH3). Animals that use this cycle, mainly amphibians and mammals, are called ureotelic.

<span class="mw-page-title-main">Ornithine</span> Chemical compound

Ornithine is a non-proteinogenic α-amino acid that plays a role in the urea cycle. Ornithine is abnormally accumulated in the body in ornithine transcarbamylase deficiency. The radical is ornithyl.

<span class="mw-page-title-main">Ornithine transcarbamylase</span> Mammalian protein found in Homo sapiens

Ornithine transcarbamylase (OTC) is an enzyme that catalyzes the reaction between carbamoyl phosphate (CP) and ornithine (Orn) to form citrulline (Cit) and phosphate (Pi). There are two classes of OTC: anabolic and catabolic. This article focuses on anabolic OTC. Anabolic OTC facilitates the sixth step in the biosynthesis of the amino acid arginine in prokaryotes. In contrast, mammalian OTC plays an essential role in the urea cycle, the purpose of which is to capture toxic ammonia and transform it into urea, a less toxic nitrogen source, for excretion.

<span class="mw-page-title-main">Carbamoyl phosphate</span> Chemical compound

Carbamoyl phosphate is an anion of biochemical significance. In land-dwelling animals, it is an intermediary metabolite in nitrogen disposal through the urea cycle and the synthesis of pyrimidines. Its enzymatic counterpart, carbamoyl phosphate synthetase I, interacts with a class of molecules called sirtuins, NAD dependent protein deacetylases, and ATP to form carbamoyl phosphate. CP then enters the urea cycle in which it reacts with ornithine to form citrulline.

<span class="mw-page-title-main">Ornithine transcarbamylase deficiency</span> Medical condition

Ornithine transcarbamylase deficiency also known as OTC deficiency is the most common urea cycle disorder in humans. Ornithine transcarbamylase, the defective enzyme in this disorder, is the final enzyme in the proximal portion of the urea cycle, responsible for converting carbamoyl phosphate and ornithine into citrulline. OTC deficiency is inherited in an X-linked recessive manner, meaning males are more commonly affected than females.

<span class="mw-page-title-main">Hepatic encephalopathy</span> Brain disease resulting from liver failure

Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Its onset may be gradual or sudden. Other symptoms may include movement problems, changes in mood, or changes in personality. In the advanced stages it can result in a coma.

<span class="mw-page-title-main">Citrullinemia</span> Medical condition

Citrullinemia is an autosomal recessive urea cycle disorder that causes ammonia and other toxic substances to accumulate in the blood.

<span class="mw-page-title-main">Argininosuccinic aciduria</span> Medical condition

Argininosuccinic aciduria is an inherited disorder that causes the accumulation of argininosuccinic acid in the blood and urine. Some patients may also have an elevation of ammonia, a toxic chemical, which can affect the nervous system. Argininosuccinic aciduria may become evident in the first few days of life because of high blood ammonia, or later in life presenting with "sparse" or "brittle" hair, developmental delay, and tremors.

<span class="mw-page-title-main">Argininosuccinate lyase</span> Mammalian protein found in Homo sapiens

The enzyme argininosuccinate lyase (EC 4.3.2.1, ASL, argininosuccinase; systematic name 2-(N ω-L-arginino)succinate arginine-lyase (fumarate-forming)) catalyzes the reversible breakdown of argininosuccinate:

<span class="mw-page-title-main">Methylmalonyl-CoA mutase deficiency</span> Medical condition

Methylmalonyl-CoA mutase is a mitochondrial homodimer apoenzyme that focuses on the catalysis of methylmalonyl CoA to succinyl CoA. The enzyme is bound to adenosylcobalamin, a hormonal derivative of vitamin B12 in order to function. Methylmalonyl-CoA mutase deficiency is caused by genetic defect in the MUT gene responsible for encoding the enzyme. Deficiency in this enzyme accounts for 60% of the cases of methylmalonic acidemia.

<span class="mw-page-title-main">Sodium phenylbutyrate</span> Chemical compound

Sodium phenylbutyrate, sold under the brand name Buphenyl among others, is a salt of an aromatic fatty acid, 4-phenylbutyrate (4-PBA) or 4-phenylbutyric acid. The compound is used to treat urea cycle disorders, because its metabolites offer an alternative pathway to the urea cycle to allow excretion of excess nitrogen.

<i>N</i>-Acetylglutamate synthase Class of enzymes

N-Acetylglutamate synthase (NAGS) is an enzyme that catalyses the production of N-acetylglutamate (NAG) from glutamate and acetyl-CoA.

<span class="mw-page-title-main">N-Acetylglutamate synthase deficiency</span> Medical condition

N-Acetylglutamate synthase deficiency is an autosomal recessive urea cycle disorder.

Carbamoyl phosphate synthetase I deficiency is an autosomal recessive metabolic disorder that causes ammonia to accumulate in the blood due to a lack of the enzyme carbamoyl phosphate synthetase I. Ammonia, which is formed when proteins are broken down in the body, is toxic if the levels become too high. The nervous system is especially sensitive to the effects of excess ammonia.

<span class="mw-page-title-main">Ornithine translocase deficiency</span> Medical condition

Ornithine translocase deficiency, also called hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome, is a rare autosomal recessive urea cycle disorder affecting the enzyme ornithine translocase, which causes ammonia to accumulate in the blood, a condition called hyperammonemia.

<span class="mw-page-title-main">Phenylacetylglutamine</span> Chemical compound

Phenylacetylglutamine is a product formed by the conjugation of phenylacetate and glutamine. It is a common metabolite that occurs naturally in human urine.

<span class="mw-page-title-main">Argininemia</span> Medical condition

Argininemia is an autosomal recessive urea cycle disorder where a deficiency of the enzyme arginase causes a buildup of arginine and ammonia in the blood. Ammonia, which is formed when proteins are broken down in the body, is toxic if levels become too high; the nervous system is especially sensitive to the effects of excess ammonia.

Transient hyperammonemia of the newborn (THAN) is an idiopathic disorder occasionally present in preterm newborns but not always symptomatic. Continuous dialysis or hemofiltration have proven to be the most effective treatment. Nutritional support and sodium benzoate have also been used to treat THAN.

<span class="mw-page-title-main">Citrullinemia type I</span> Medical condition

Citrullinemia type I (CTLN1), also known as arginosuccinate synthetase deficiency, is a rare disease caused by a deficiency in argininosuccinate synthetase, an enzyme involved in excreting excess nitrogen from the body. There are mild and severe forms of the disease, which is one of the urea cycle disorders.

Carbamoyl phosphate synthetase III is one of the three isoforms of the carbamoyl phosphate synthetase, an enzyme that catalyzes the active production of carbamoyl phosphate in many organisms.

References

  1. Riggio, O.; Merli, M.; Capocaccia, L.; Caschera, M.; Zullo, A.; Pinto, G.; Gaudio, E.; Franchitto, A.; Spagnoli, R.; D'Aquilino, E. (September 1992). "Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis". Hepatology. 16 (3): 785–789. doi: 10.1002/hep.1840160326 . ISSN   0270-9139. PMID   1505922. S2CID   1141979.
  2. 1 2 3 4 Limón ID, Angulo-Cruz I, Sánchez-Abdon L, Patricio-Martínez A (2021). "Disturbance of the Glutamate-Glutamine Cycle, Secondary to Hepatic Damage, Compromises Memory Function". Front Neurosci. 15: 578922. doi: 10.3389/fnins.2021.578922 . PMC   7873464 . PMID   33584185.
  3. 1 2 3 4 5 6 Ali, Rimsha; Nagalli, Shivaraj (7 April 2023). "Hyperammonemia". StatPearls Publishing. PMID   32491436 . Retrieved 6 September 2024.
  4. 1 2 3 4 5 Alfadhel M, Mutairi FA, Makhseed N, Jasmi FA, Al-Thihli K, Al-Jishi E, AlSayed M, Al-Hassnan ZN, Al-Murshedi F, Häberle J, Ben-Omran T (2016). "Guidelines for acute management of hyperammonemia in the Middle East region". Ther Clin Risk Manag. 12: 479–487. doi: 10.2147/TCRM.S93144 . PMC   4820220 . PMID   27099506.
  5. 1 2 Colombo JP, Peheim E, Kretschmer R, Dauwalder H, Sidiropoulos D (April 1984). "Plasma ammonia concentrations in newborns and children". Clin Chim Acta. 138 (3): 283–291. doi:10.1016/0009-8981(84)90135-9. PMID   6723064.
  6. Donn, S. M.; Banagale, R. C. (1 January 1984). "Neonatal Hyperammonemia". Pediatrics in Review. 5 (7): 203–208. doi:10.1542/pir.5-7-203. ISSN   0191-9601.
  7. 1 2 Häberle J (January 2011). "Clinical practice: the management of hyperammonemia". Eur J Pediatr. 170 (1): 21–34. doi:10.1007/s00431-010-1369-2. PMID   21165747.
  8. Mukherjee, Arghya; Singh, Santosh (2024-11-17). "Andrographolide prevents acute hyperammonemia-induced motor dysfunction in rats. Evidences for its mechanism of action". Phytomedicine Plus: 100679. doi:10.1016/j.phyplu.2024.100679. ISSN   2667-0313.
  9. 1 2 Häberle, Johannes; Chakrapani, Anupam; Ah Mew, Nicholas; Longo, Nicola (December 2018). "Hyperammonaemia in classic organic acidaemias: a review of the literature and two case histories". Orphanet Journal of Rare Diseases. 6 (13): 219. doi: 10.1186/s13023-018-0963-7 . PMC   6282273 . PMID   30522498.
  10. 1 2 Nepal SP, Unoki T, Inoue T, Nakasato T, Naoe M, Ogawa Y, Omizu M, Kato R, Sugishita H, Oshinomi K, Morita J, Maeda Y, Shichijo T. A case of hyperammonemia in a patient with urinary tract infection and urinary retention. Urol Sci [serial online] 2020 [cited 2021 Apr 3];31:82-4. Available from: https://www.e-urol-sci.com/text.asp?2020/31/2/82/283250
  11. Kenzaka T, Kato K, Kitao A, et al. Hyperammonemia in Urinary Tract Infections. PLoS One. 2015;10(8):e0136220. Published 2015 Aug 20. doi:10.1371/journal.pone.0136220
  12. 1 2 Chapter 298 – Inborn Errors of Metabolism and Continuous Renal Replacement Therapy Archived 2013-07-01 at the Wayback Machine in: John J. Ratey MD; Claudio Ronco MD (2008). Critical Care Nephrology: Expert Consult - Online and Print. Philadelphia: Saunders. ISBN   978-1-4160-4252-5. ISBN   9781416042525
  13. Chawla, Jasvinder (12 September 2022). "Hyperammonemia". Medscape. Retrieved 18 March 2024.
  14. "Ammonul (Sodium Phenylacetate and Sodium Benzoate Injection) clinical pharmacology - prescription drugs and medications at RxList". Archived from the original on 2008-06-16. Retrieved 2008-06-26.
  15. Bloom, Patricia; Tapper, Elliot (November 2023). "Lactulose in cirrhosis: Current understanding of efficacy, mechanism, and practical considerations". Hepatology Communications. 7 (11): e0295. doi:10.1097/HC9.0000000000000295. PMC   10578757 . PMID   37820287.
  16. Elbaba, Mostafa. "IPE Simulation Enhances the Quality of Care in Neonatal Hyperammonemia". Cureus Journal of Medical Science.